Sievert W, Altraif I, Razavi HA, et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int 2011; 31 Suppl 2: 61-80.
Hajarizadeh B, Grebely J, McManus H, et al. Chronic hepatitis C burden and care cascade in Australia in the era of interferon-based treatment. J Gastroenterol Hepatol 2017; 32: 229-236.
Kirby Institute. Hepatitis B and C in Australia: annual surveillance report supplement 2016. Sydney: Kirby Institute, University of New South Wales, 2016.
Kirby Institute. HIV, viral hepatitis and sexually transmissible infections in Australia: annual surveillance report 2021. Hepatitis C. Sydney: Kirby Institute, UNSW Sydney, 2021. https://kirby.unsw.edu.au/report/asr2021 (accessed Aug 2022).
Hajarizadeh B, Grebely J, Byrne M, et al. Evaluation of hepatitis C treatment-as-prevention within Australian prisons (StoP-C): a prospective cohort study. Lancet Gastroenterol Hepatol 2021; 7: 533-546.
Valerio H, Alavi M, Law M, et al. High hepatitis C treatment uptake among people with recent drug dependence in New South Wales, Australia. J Hepatol 2021; 74: 293-302.
Scott N, Sacks-Davis R, Wade AJ, et al. Australia needs to increase testing to achieve hepatitis C elimination. Med J Aust 2020; 212: 365-370.
Sievert W, Razavi H, Estes C, et al. Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia. J Gastroenterol Hepatol 2014; 29 Suppl 1: 1-9.
World Health Organization. Global health sector strategy on viral hepatitis 2016–2021: towards ending viral hepatitis. Geveva: WHO, 2016.
Ramachandran J, Kaambwa B, Muller K, et al. Cost effectiveness of treatment models of care for hepatitis C: the South Australian state-wide experience. Eur J Gastroenterol Hepatol 2020; 32: 1381-1389.
Arora S, Thornton K, Murata G, et al. Outcomes of treatment for hepatitis C virus infection by primary care providers. N Engl J Med 2011; 364: 2199-2207.
Baker D, Alavi M, Erratt A, et al. Delivery of treatment for hepatitis C virus infection in the primary care setting. Eur J Gastroenterol Hepatol 2014; 26: 1003-1009.
MacLachlan J, Thomas L, Cowie C, Allard N. Hepatitis C Mapping Project: estimates of geographic diversity in chronic hepatitis C prevalence, diagnosis, monitoring and treatment – National Report 2016. Sydney: Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine, 2018.
Scott N, Hainsworth SW, Sacks-Davis R, et al. Heterogeneity in hepatitis C treatment prescribing and uptake in Australia: a geospatial analysis of a year of unrestricted treatment access. J Virus Erad 2018; 4: 108-114.
Biddle ML, Adler NR, Heath M, et al. Nurse-led clinic: effective and efficient delivery of assessment and review of patients with hepatitis B and C. Intern Med J 2014; 44: 581-585.
Nazareth S, Piercey C, Tibbet P, Cheng W. Innovative practice in the management of chronic hepatitis C: introducing the nurse practitioner model. Aust J Adv Nurs 2008; 25 (4): 107-113.
Wade AJ, Macdonald DM, Doyle JS, et al. The cascade of care for an Australian community-based hepatitis C treatment service. PloS One 2015; 10: e0142770.
Butler T, Boonwaat L, Hailstone S, et al. The 2004 Australian prison entrants’ blood-borne virus and risk behaviour survey. Aust N Z J Public Health 2007; 31: 44-50.
Bate JP, Colman AJ, Frost PJ, et al. High prevalence of late relapse and reinfection in prisoners treated for chronic hepatitis C. J Gastroenterol Hepatol 2010; 25: 1276-1280.
Lloyd AR, Clegg J, Lange J, et al. Safety and effectiveness of a nurse-led outreach program for assessment and treatment of chronic hepatitis C in the custodial setting. Clin Infect Dis 2013; 56: 1078-1084.
Papaluca T, McDonald L, Craigie A, et al. Outcomes of treatment for hepatitis C in prisoners using a nurse-led, statewide model of care. J Hepatol 2019; 70: 839-846.
Papaluca TJ, Tambakis G, Iser D, Thompson AJ. Effective prison-based treatment and linkage to care after release. Lancet Infect Dis 2019; 19: 1171.
Papaluca T, Hellard ME, Thompson AJV, Lloyd AR. Scale-up of hepatitis C treatment in prisons is key to national elimination. Med J Aust 2019; 210: 391-393.e1.
Aspinall EJ, Corson S, Doyle JS, et al. Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. Clin Infect Dis 2013; 57 Suppl 2: S80-S89.
Hellard M, Rolls DA, Sacks-Davis R, et al. The impact of injecting networks on hepatitis C transmission and treatment in people who inject drugs. Hepatology 2014; 60: 1861-1870.
Jeffrey GP, MacQuillan G, Chua F, et al. Hepatitis C virus eradication in intravenous drug users maintained with subcutaneous naltrexone implants. Hepatology 2007; 45: 111-117.
Fragomeli V, Weltman M. Addressing viral hepatitis in the opiate substitution setting: an integrated nursing model of care. J Gastroenterol Hepatol 2015; 30 Suppl 2: 6-11.
Bruce RD, Eiserman J, Acosta A, et al. Developing a modified directly observed therapy intervention for hepatitis C treatment in a methadone maintenance program: implications for program replication. Am J Drug Alcohol Abuse 2012; 38: 206-212.
Nazareth S, Kontorinis N, Muwanwella N, et al. Successful treatment of patients with hepatitis C in rural and remote Western Australia via telehealth. J Telemed Telecare 2013; 19 (2): 101-106.
Ramachandran J, Budd S, Slattery H, et al. Hepatitis C virus infection in Australian psychiatric inpatients: a multicenter study of seroprevalence, risk factors and treatment experience. J Viral Hepat 2019; 26: 609-612.
Braude MR, Phan T, Dev A, Sievert W. Determinants of hepatitis C virus prevalence in people with serious mental illness: a systematic review and meta-analysis. J Clin Psychiatry 2021; 83: 21r14079.
Ferguson C, Ralton L, McCartney EM, et al. Point of care testing for hepatitis C in in the priority settings of mental health, prisons and drug and alcohol facilities [abstract THU272]. J Hepatol 2022; 77 Suppl 1: S228.
Conway A, Stevens A, Murray C, et al. Hepatitis C treatment uptake following dried blood spot testing for hepatitis C RNA in New South Wales, Australia: the NSW DBS Pilot [abstract]. 13th Australasian Viral Hepatitis Conference; Brisbane (Australia); 2022.
Valerio H, Alavi M, Silk D, et al. Progress towards elimination of hepatitis C infection among people who inject drugs in Australia: the ETHOS Engage study. Clin Infect Dis 2021; 73: e69-e78.
Kemp W, Levy M, Weltman M, Lubel J. Australian Liver Association (ALA) expert consensus recommendations for the use of transient elastography in chronic viral hepatitis. J Gastroenterol Hepatol 2015; 30: 453-462.
European Association for Study of Liver; Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH clinical practice guidelines: non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol 2015; 63: 237-264.
Afdhal N, Reddy KR, Nelson DR, et al; ION-2 Investigators. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370: 1483-1493.
Afdhal N, Zeuzem S, Kwo P, et al; ION-1 Investigators. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370: 1889-1898.
de Franchis R, Bosch J, Garcia-Tsao G, et al; Baveno VII Faculty. Baveno VII – Renewing consensus in portal hypertension. J Hepatol 2022; 76: 959-974.
National Health and Medical Research Council. Australian guidelines to reduce health risks from drinking alcohol. Canberra: NHMRC, 2020. https://www.nhmrc.gov.au/about-us/publications/australian-guidelines-reduce-health-risks-drinking-alcohol (accessed Oct 2022).
Australasian Hepatology Association. AHA consensus guidelines for the provision of adherence support to patients with hepatitis C on direct acting antivirals. Brisbane: AHA, 2016. https://www.hepatologyassociation.com.au/resources/publications (accessed Nov 2022).
Richmond JA, Sheppard-Law S, Mason S, Warner SL. The Australasian Hepatology Association consensus guidelines for the provision of adherence support to patients with hepatitis C on direct acting antivirals. Patient Prefer Adherence 2016; 10: 2479-2489.
Feld JJ, Jacobson IM, Hézode C, et al; ASTRAL-1 Investigators. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med 2015; 373: 2599-2607.
Foster GR, Afdhal N, Roberts SK, et al; ASTRAL-2 Investigators, ASTRAL-3 Investigators. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med 2015; 373: 2608-2617.
Jacobson IM, Lawitz E, Gane EJ, et al. Efficacy of 8 weeks of sofosbuvir, velpatasvir, and voxilaprevir in patients with chronic HCV infection: 2 Phase 3 randomized trials. Gastroenterology 2017; 153: 113-122.
Zuckerman E, Gutierrez JA, Dylla DE, et al. Eight weeks of treatment with glecaprevir/pibrentasvir is safe and efficacious in an integrated analysis of treatment-I patients with hepatitis C virus infection. Clin Gastroenterol Hepatol 2020; 18: 2544-2553.
Lampertico P, Mauss S, Persico M, et al. Real-world clinical practice use of 8-week glecaprevir/pibrentasvir in treatment-I patients with compensated cirrhosis. Adv Ther 2020; 37: 4033-4042.
Zeuzem S, Foster GR, Wang S, et al. Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection. N Engl J Med 2018; 378: 354-369.
Bourlière M, Gordon SC, Flamm SL, et al; POLARIS-1 and POLARIS-4 Investigators. Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection. N Engl J Med 2017; 376: 2134-2146.
Jonas MM, Squires RH, Rhee SM, et al. Pharmacokinetics, safety, and efficacy of glecaprevir/pibrentasvir in adolescents with chronic hepatitis C virus: Part 1 of the DORA Study. Hepatology 2020; 71: 456-462.
Jonas MM, Romero R, Sokal EM, et al. Safety and efficacy of sofosbuvir/velpatasvir in pediatric patients 6 to <18 years old with chronic hepatitis C infection [abstract 748]. The Liver Meeting; Boston (USA); 8–12 November 2019.
Jonas MM, Lon HK, Rhee S, et al. Pharmacokinetics of glecaprevir/pibrentasvir in children with chronic HCV infection: interim analysis of part 2 of the DORA study [abstract 1551]. The Liver Meeting; Boston (USA); 8–12 November 2019.
Papaluca T, O’Keefe J, Bowden S, et al. Prevalence of baseline HCV NS5A resistance associated substitutions in genotype 1a, 1b and 3 infection in Australia. J Clin Virol 2019; 120: 84-87.
Ong AT, Tay E, Dwyer DE, George J, Douglas MW. Pre-treatment antiviral resistance in Australians with chronic hepatitis C: prevalence of NS3 and NS5A resistance data in the state of New South Wales. Antivir Ther 2019; 24: 281-290.
Poordad F, Felizarta F, Asatryan A, et al. Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment. Hepatology 2017; 66: 389-397.
Poordad F, Pol F, Asatryan A, et al. MAGELLAN-1, Part 2: Glecaprevir and pibrentasvir for 12 or 16 weeks in patients with chronic HCV genotype 1 or 4 and prior direct-acting antiviral treatment failure. Gastroenterology 2017; 152 Suppl 1: S1057.
Gane E, de Ledinghen V, Dylla DE, et al. Positive predictive value of sustained virologic response 4 weeks posttreatment for achieving sustained virologic response 12 weeks posttreatment in patients receiving glecaprevir/pibrentasvir in Phase 2 and 3 clinical trials. J Viral Hepat 2021; 28: 1635-1642.
Sulkowski M, Feld JJ, Reau NS, et al. Concordance of SVR 4-12-24 timepoints in an era of reduced sustained virologic response (SVR) determination. J Hepatol 2021; 75 Suppl 2: S294-S803.
de Franchis R; Baveno VI Faculty. Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol 2015; 63: 743-752.
Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-1022.
European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-943.
Transplantation Society of Australia and New Zealand, Organ and Tissue Authority. Clinical guidelines for organ transplantation from deceased donors. Version 1.10 – October 2022. Sydney: TSANZ, 2022. https://tsanz.com.au/guidelinesethics-documents/tsanz-clinical-guidelines.htm (accessed Nov 2022).
Charlton M, Everson GT, Flamm SL, et al; SOLAR-1 Investigators. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 2015; 149: 649-659.
Gane EJ, Manns MP, McCaughan G, et al. High efficacy of ledipasvir/sofosbuvir with ribavirin in patients with decompensated cirrhosis or liver transplantation and HCV infection: combined efficacy from the SOLAR-1 and SOLAR-2 trials [abstract 1049]. Hepatology 2015; 62 Suppl 1: 722A-723A.
Curry MP, Forns X, Chung R, et al. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. Gastroenterology 2015; 148: 100-107.e1.
Lawitz E, Poordad F, Gutierrez JA, et al. SVR12 results from the phase II, open-label IMPACT study of simeprevir (SMV) in combination with daclatasvir (DCV) and sofosbuvir (SOF) in treatment-naïve and -experienced patients with chronic HCV genotype 1/4 infection and decompensated liver disease [abstract 39]. Hepatology 2015; 62 Suppl 1: 227A.
Martini S, Donato MF, Mazzarelli C, et al. The Italian compassionate use of sofosbuvir (ITACOPS) in patients with HCV-related cirrhosis waitlisted for liver transplantation: virological and clinical outcomes from a national real-life experience [abstract LB-26]. Hepatology 2015; 62 (6 Suppl): 1395A.
McCaughan G, Roberts SK, Strasser SI, et al. The TOSCAR study: sofosbuvir and daclatasvir therapy for decompensated HCV cirrhosis with MELD scores > 15: what is the point of no return? [abstract 1077]. Hepatology 2015; 62 Suppl 1: 738A.
Welzel TM, Petersen J, Ferenci P, et al. Safety and efficacy of daclatasvir plus sofosbuvir with or without ribavirin for the treatment of chronic HCV genotype 3 infection: interim results of a multicenter European compassionate use program [abstract 37]. Hepatology 2015; 62 Suppl 1: 225A-226A.
Curry MP, O’Leary JG, Bzowej N, et al; ASTRAL-4 Investigators. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med 2015; 373: 2618-2628.
El-Sherif O, Jiang ZG, Tapper EB, et al. Baseline factors associated with improvements in decompensated cirrhosis after direct-acting antiviral therapy for hepatitis C virus infection. Gastroenterology 2018; 154: 2111-2121.e8.
Coilly A, Pageaux G-P, Houssel-Debry P, et al. Improving liver function and delisting of patients awaiting liver transplantation for HCV cirrhosis: do we ask too much to DAA? [abstract 95]. Hepatology 2015; 62 Suppl 1: 257A.
Australia and New Zealand Liver Transplant Registry. 25th registry report. Brisbane: ANZLT, 2014. https://www.anzlitr.org/annual-reports (accessed Nov 2022).
Howell J, Majumdar A, Fink MA, et al. Turning the tide on hepatitis C virus-related liver transplantation: the return on investment in hepatitis C virus treatment in Australia and New Zealand. Liver Transpl 2022; 28: 236-246.
Burra P, De Martin E, Zanetto A, et al. Hepatitis C virus and liver transplantation: where do we stand? Transpl Int 2016; 29 (2): 135-152.
Verna EC, Abdelmessih R, Salomao MA, et al. Cholestatic hepatitis C following liver transplantation: an outcome-based histological definition, clinical predictors, and prognosis. Liver Transpl 2013; 19 (1): 78-88.
Reau N, Kwo PY, Rhee S, et al. MAGELLAN-2: safety and efficacy of glecaprevir/pibrentasvir in liver or renal transplant adults with chronic hepatitis C genotype 1–6 infection [abstract LBO-03]. J Hepatol 2017; 66 (1 Suppl): S90-S91.
Ueda Y, Kobayashi T, Ikegami T, et al. Efficacy and safety of glecaprevir and pibrentasvir treatment for 8 or 12 weeks in patients with recurrent hepatitis C after liver transplantation: a Japanese multicenter experience. J Gastroenterol 2019; 54: 660-666.
Wiesner RH, Sorrell M, Villamil F; International Liver Transplantation Society Expert Panel. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis Liver Transpl 2003; 9 (11): S1-S9.
Leroy V, Dumortier J, Coilly A, et al. Efficacy of sofosbuvir and daclatasvir in patients with fibrosing cholestatic hepatitis C after liver transplantation. Clin Gastroenterol Hepatol 2015; 13: 1993-2001.
Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001; 33: 562-569.
Weber R, Sabin CA, Friis-Møller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166: 1632-1641.
Kitahata MM, Gange SJ, Abraham AG, et al; NA-ACCORD Investigators. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009; 360: 1815-1826.
Molina JM, Orkin C, Iser DM, et al; PHOTON-2 study team. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study. Lancet 2015; 385: 1098-1106.
Naggie S, Cooper C, Saag M, et al; ION-4 Investigators. Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med 2015; 373: 705-713.
Osinusi A, Townsend K, Kohli A, et al. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. JAMA 2015; 313: 1232-1239.
Sulkowski MS, Eron JJ, Wyles D, et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA 2015; 313: 1223-1231.
Sulkowski MS, Naggie S, Lalezari J, et al. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA 2014; 312: 353-361.
Wyles DL, Ruane PJ, Sulkowski MS, et al; ALLY-2 Investigators. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med 2015; 373: 714-725.
Bradshaw D, Matthews G, Danta M. Sexually transmitted hepatitis C infection: the new epidemic in MSM? Curr Opin Infect Dis 2013; 26: 66-72.
National HIV Testing Policy Expert Reference Committee. 2011 National HIV testing policy. Version 1.1. Canberra: Commonwealth of Australia, 2011.
National HCV Testing Policy Expert Reference Committee. 2012 National hepatitis C testing policy. Version 1.1. Canberra: Commonwealth of Australia, 2012.
Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine Sub-Committee for Guidance on HIV Management in Australia. Antiretroviral guidelines: US DHHS guidelines with Australian commentary. https://arv.ashm.org.au (accessed Nov 2022).
Hull MC, Cescon A, Raboud A, et al. Switching from first antiretroviral therapy regimen while virologically suppressed is associated with increased risk of subsequent virologic failure [abstract TUAB0103]. AIDS 2014: 20th International AIDS Conference; Melbourne (Australia); 20–25 July 2014.
Wyles D, Bräu N, Kottilil S, et al; ASTRAL-5 Investigators. Sofosbuvir and velpatasvir for the treatment of hepatitis C virus in patients coinfected with human immunodeficiency virus type 1: an open-label, Phase 3 study. Clin Infect Dis 2017; 65: 6-12.
Kirby B, Mathias A, Rossi S, et al. No clinically significant pharmacokinetic interactions between sofosbuvir (GS-7977) and HIV antiretrovirals atripla, rilpivirine, darunavir/ritonavir, or raltegravir in healthy volunteers. 63rd Annual Meeting of the American Association for the Study of Liver Diseases; Boston (USA); 9–11 Nov 2012.
European Association For The Study Of The Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-185.
US Food and Drug Administration. FDA Drug Safety Communication: FDA warns about the risk of hepatitis B reactivating in some patients treated with direct-acting antivirals for hepatitis C. Silver Spring, Md: FDA, 2016. http://www.fda.gov/Drugs/DrugSafety/ucm522932.htm (accessed Dec 2016).
Liu CJ, Chuang WL, Lee CM, et al. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Gastroenterology 2009; 136: 496-504.
Sulkowski MS, Chuang WL, Kao JH, et al. No evidence of reactivation of hepatitis B virus among patients treated with ledipasvir-sofosbuvir for hepatitis C virus infection. Clin Infect Dis 2016; 63: 1202-1204.
Wang C, Ji D, Chen J, et al. Hepatitis due to reactivation of hepatitis B virus in endemic areas among patients with hepatitis C treated with direct-acting antiviral agents. Clin Gastroenterol Hepatol 2017; 15: 132-136.
Liu C-H, Chen C-Y, Su W-W, et al. Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment. Gut 2021; 71: 176-184.
Lawitz E, Landis CS, Maliakkal BJ, et al. Safety and efficacy of treatment with once daily ledipasvir/sofobuvir (90/400 mg) for 12 weeks in genotype 1 HCV infected patients with severe renal impairment [abstract IDDF2018-ABS-0110]. Gut 2018; 67 Suppl 2: A99.
Desnoyer A, Pospai D, Lê MP, et al. Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C. J Hepatol 2016; 65: 40-47.
Nazario HE, Ndungu M, Modi AA. Sofosbuvir and simeprevir in hepatitis C genotype 1-patients with end-stage renal disease on haemodialysis or GFR <30 mL/min. Liver Int 2016; 36: 798-801.
Saxena V, Koraishy FM, Sise ME, et al; HCV-TARGET. Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function. Liver Int 2016; 36: 807-816.
Bruchfeld A, Lindahl K, Schvarcz R, Stahle L. Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis. Ther Drug Monit 2002; 24: 701-708.
Gane E, Lawitz E, Pugatch D, et al. Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment. N Engl J Med 2017; 377: 1448-1455.
Johnson RJ, Willson R, Yamabe H, et al. Renal manifestations of hepatitis C virus infection. Kidney Int 1994; 46: 1255-1263.
Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol 2013; 10: 553-562.
Doyle JS, van Santen DK, Iser D, et al. Microelimination of hepatitis C among people with human immunodeficiency virus coinfection: declining incidence and prevalence accompanying a multicenter treatment scale-up trial. Clin Infect Dis 2021; 73: e2164-e2172.
Martinello M, Yee J, Bartlett SR, et al. Moving towards hepatitis C microelimination among people living with human immunodeficiency virus in Australia: the CEASE study. Clin Infect Dis 2020; 71: 1502-1510.
Matthews GV, Bhagani S, Van der Valk M, et al. Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection. J Hepatol 2021; 75: 829-839.
Martinello M, Orkin C, Cooke G, et al. Short-duration pan-genotypic therapy with glecaprevir/pibrentasvir for 6 weeks among people with recent hepatitis C viral infection. Hepatology 2020; 72: 7-18.
Deterding K, Spinner CD, Schott E, et al. Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study. Lancet Infect Dis 2017; 17: 215-222.
Boerekamps A, De Weggheleire A, van den Berk GE, et al. Treatment of acute hepatitis C genotypes 1 and 4 with 8 weeks of grazoprevir plus elbasvir (DAHHS2): an open-label, multicentre, single-arm, phase 3b trial. Lancet Gastroenterol Hepatol 2019; 4: 269-277.
Popping S, Hullegie SJ, Boerekamps A, et al. Early treatment of acute hepatitis C infection is cost-effective in HIV-infected men-who-have-sex-with-men. PLoS One 2019; 14: e0210179.
Matthews GV, Pham ST, Hellard M, et al. Patterns and characteristics of hepatitis C transmission clusters among HIV-positive and HIV-negative individuals in the Australian trial in acute hepatitis C. Clin Infect Dis 2011; 52: 803-811.
Wandeler G, Gsponer T, Bregenzer A, et al; Swiss HIV Cohort Study. Hepatitis C virus infections in the Swiss HIV Cohort Study: a rapidly evolving epidemic. Clin Infect Dis 2012; 55: 1408-1416.
Danta M, et al. Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. AIDS 2007; 21: 983-991.
Robaeys G, Grebely J, Mauss S, et al; International Network on Hepatitis in Substance Users. Recommendations for the management of hepatitis C virus infection among people who inject drugs. Clin Infect Dis 2013; 57 Suppl 2: S129-S137.
Blackard JT, Shata MT, Shire NJ, Sherman KE. Acute hepatitis C virus infection: a chronic problem. Hepatology 2008; 47: 321-331.
Grebely J, Matthews GV, Petoumenos K, Dore GJ. Spontaneous clearance and the beneficial impact of treatment on clearance during recent hepatitis C virus infection. J Viral Hepat 2010; 17: 896.
Hajarizadeh B, Grady B, Page K, et al; InC3 Study Group. Patterns of hepatitis C virus RNA levels during acute infection: the InC3 study. PLoS One 2015; 10 (4): e0122232.
Hofer H, Watkins-Riedel T, Janata O, et al. Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load. Hepatology 2003; 37: 60-64.
Lubel JS, Roberts SK, Strasser SI, et al. Australian recommendations for the management of hepatocellular carcinoma: a consensus statement. Med J Aust 2021; 214: 475-483.
Veldt BJ, Heathcote EJ, Wedemeyer H, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007; 147: 677-684.
van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308: 2584-2593.
Morgan RL, Baack B, Smith BD, et al. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med 2013; 158 (5 Pt 1): 329-337.
Nahon P, Bourcier V, Layese R, et al. Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications. Gastroenterology 2017; 152: 142-156.
Kanwal F, Kramer J, Asch SM, et al. Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents. Gastroenterology 2017; 153: 996-1005.
Ioannou GN, Green PK, Beste LA, et al. Development of models estimating the risk of hepatocellular carcinoma after antiviral treatment for hepatitis C. J Hepatol 2018; 69: 1088-1098.
Calvaruso V, Cabibbo G, Cacciola I, et al. Incidence of hepatocellular carcinoma in patients with HCV-associatedcirrhosis treated with direct-acting antiviral agents. Gastroenterology 2018; 155: 411-421.
Li DK, Ren Y, Fierer DS, et al. The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: an ERCHIVES study. Hepatology 2018; 67: 2244-2253.
Kanwal F, Kramer JR, Asch SM, et al. Long-term risk of hepatocellular carcinoma in HCV patients treated with direct acting antiviral agents. Hepatology 2020; 71: 44-55.
Reig M, Mariño Z, Perelló C, et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol 2016; 65: 719-726.
Conti F, Buonfiglioli F, Scuteri A, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol 2016; 65: 727-733.
Waziry R, Hajarizadeh B, Grebely J, et al. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression. J Hepatol 2017; 67: 1204-1212.
Singal AG, Rich NE, Mehta N, et al. Direct-acting antiviral therapy for hepatitis C virus infection is associated with increased survival in patients with a history of hepatocellular carcinoma. Gastroenterology 2019; 157: 1253-1263.e2.
Singal AG, Lim JK, Kanwal F. AGA clinical practice update on interaction between oral direct-acting antivirals for chronic hepatitis C infection and hepatocellular carcinoma: expert review. Gastroenterology 2019; 156: 2149-2157.
He S, Lockart I, Alavi M, et al. Systematic review with meta-analysis: effectiveness of direct-acting antiviral treatment for hepatitis C in patients with hepatocellular carcinoma. Aliment Pharmacol Ther 2020; 51: 34-52.
Andrews J, Guyatt G, Oxman AD, et al. GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol 2013; 66: 719-725.